Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 2/3 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2Thoracic 1

Conditions

Mesothelioma, Malignant 1Advanced or Metastatic Solid Tumors 1

Interventions

pembrolizumab 257Cyclophosphamide 241Specimen Handling 198fludarabine 173Magnetic Resonance Spectroscopy 173Biopsy 147Nivolumab 120Carboplatin 97Radiotherapy 92Paclitaxel 85venetoclax 82Cisplatin 80Gemcitabine 79fludarabine phosphate 78Injections 68Ipilimumab 64Dexamethasone 62atezolizumab 59Bevacizumab 58Cetuximab 57Radiation 55Fluorouracil 55Azacitidine 55durvalumab 54Radiosurgery 52Temozolomide 47Rituximab 44Oxaliplatin 44Docetaxel 44Irinotecan 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Combined Modality Therapy × 1 year × Clear all
NCT06251310 2026-05-08

SW-682 in Advanced Solid Tumors

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 1 Recruiting
186 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05957081 2025-12-30

MarkV-01

PharmAbcine

Phase 1 Recruiting
67 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡